As the Q4 earnings season wraps, let’s dig into this quarter’s best and worst performers in the life sciences tools & ...

10X Genomics, Inc. is a life science technology company, which engages in building products to interrogate, understand and master biology. Its integrated solutions include single cell ...

BofA analyst Michael Ryskin lowered the firm’s price target on 10x Genomics (TXG) to $12 from $16 and keeps a Neutral rating on the shares.

10x Genomics, Inc., a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the Americas, Europe, the Middle East ...

PLEASANTON, Calif., April 14, 2025 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, announced it will report financial results for the first quarter ...

Given this risk, we thought we'd take a look at whether 10x Genomics (NASDAQ:TXG) shareholders should be worried about its cash burn. In this report, we will consider the company's annual negative ...

In a report released today, Luke Sergott from Barclays maintained a Buy rating on 10x Genomics (TXG – Research Report), with a price target of $12.00. The company’s shares closed yesterday at $8.67.

10x Genomics' talented, dedicated science professionals have a distinguished record of creating innovative instruments, reagents and software that analyze biological systems at a resolution that ...

PLEASANTON, Calif., April 14, 2025 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, announced it will report financial results for the first quarter ...